- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- 10 Stock Picks for This 'Gradual Recovery'
- Recovery's Real Shape? Not a W: Stock Picker
- Market Direction into 2010 Depends on This: Analysts
- Prep Your Portfolio for Next Week: Stock Pickers
- Art Cashin: Why Markets Face 'Enormous' 1-Day Swings
- India or China: Which Is the Better Place to Invest?
- What Traders Expect From This Bank Stock
- Gold Is a Bad Inflation Hedge—Like Oil: Stock Picker
MOST SHARED
- Seeking Innovation in Health Care
- Driving Health Care Innovation
- Next Week’s Top IPO
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- Herbalife Vs. Hedge Funds
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Israel: Leader of Business Innovation
- Warren Buffett and Bill Gates: Keeping America Great
- Burned by Yahoo!, Disney and More
- Novo Nordisk CEO on Diabetes Epidemic
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Dollar General Trades Higher After Its IPO
- Fed Reform? Not So Fast.
- Oil Next Week: What Traders Will Be Watching
- Hedge Fund Billionaire Paulson Reports New Citi Stake
- Cramer: 5 Earnings Reports to Watch Next Week
- Court Rejects 'Clawbacks' for Alleged Stanford Victims
- Tax Credit Sparking First-Time Home Sales: Realtors
- Investors Cut Back US Stocks for Bigger Growth Abroad
- Cities With the Most Home Price Reductions
- White House Plans to Freeze Spending to Cut Deficit
- This Year's Biggest Thanksgiving Leftover: Cash
- Oil Next Week: What Traders Will Be Watching
RSS FEED
CNBC Stock Blog
Text Size 
Pharmaceutical companies may not have been immune to the weak economy, but its effects on pharma “have not been as dramatic as some of the other sectors,” said Catherine Arnold, senior pharmaceuticals analyst at Credit Suisse.
Pfizer reported a better-than-expected profit as cost-cutting helped offset sharply lower sales of its cholesterol fighter and its anti-smoking drug on Tuesday morning, while Bristol-Myers Squibb said its profit slipped 3 percent, as negative foreign exchange factors and falling sales of its cancer medicine more than offset higher revenue from other medicines.
“Although neither [Pfizer or Bristol-Myers Squibb] are necessarily the major pharmaceuticals that produce anti-viral medicine for pandemics, big drug companies do play a role in having an important mission,” said Arnold.
She named her favorite makers of anti-viral drugs.
Arnold's Picks:
Roche
Gilead [GILD
Loading...
()
]
GlaxoSmithKline [GSK
Loading...
()
]
Arnold also said she has an outperform rating on Pfizer [PFE
Loading...
()
] and a neutral rating on Bristol-Myers Squibb [BMY
Loading...
()
].
More Swine Flu News From CNBC.com
- Companies Start Initial Work on Vaccine
- Deathtoll Rises in Mexico
- Flu Impact: Latin America Stock IndexesDisclosure:
Arnold does not own shares of any of the companies mentioned above.
Data is a real-time snapshot *Data is delayed at least 15 minutes